165 related articles for article (PubMed ID: 33871208)
1. Comparison of effectiveness of interventions in reducing mortality in patients of toxic epidermal necrolysis: A network meta-analysis.
Patel TK; Patel PB; Thakkar S
Indian J Dermatol Venereol Leprol; 2021; 87(5):628-644. PubMed ID: 33871208
[TBL] [Abstract][Full Text] [Related]
2. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis.
Tsai TY; Huang IH; Chao YC; Li H; Hsieh TS; Wang HH; Huang YT; Chen CY; Cheng YC; Kuo PH; Huang YC; Tu YK
J Am Acad Dermatol; 2021 Feb; 84(2):390-397. PubMed ID: 32898587
[TBL] [Abstract][Full Text] [Related]
3. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.
Zimmermann S; Sekula P; Venhoff M; Motschall E; Knaus J; Schumacher M; Mockenhaupt M
JAMA Dermatol; 2017 Jun; 153(6):514-522. PubMed ID: 28329382
[TBL] [Abstract][Full Text] [Related]
4. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL
Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921
[TBL] [Abstract][Full Text] [Related]
6. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.
Houschyar KS; Tapking C; Borrelli MR; Puladi B; Ooms M; Wallner C; Duscher D; Pförringer D; Rein S; Reumuth G; Schulz T; Nietzschmann I; Maan ZN; Grieb G; Philipp-Dormston WG; Branski LK; Siemers F; Lehnhardt M; Schmitt L; Yazdi AS
J Wound Care; 2021 Dec; 30(12):1012-1019. PubMed ID: 34881995
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
Schneider JA; Cohen PR
Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
Mohanty S; Das A; Ghosh A; Sil A; Gharami RC; Bandyopadhyay D; Das NK
Indian J Dermatol Venereol Leprol; 2017; 83(3):312-316. PubMed ID: 28366923
[TBL] [Abstract][Full Text] [Related]
10. Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches.
Singh N; Phillips M
Skin Therapy Lett; 2022 Sep; 27(5):7-13. PubMed ID: 36469487
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Active Treatments for Toxic Epidermal Necrolysis.
Kinoshita Y; Saeki H
J Nippon Med Sch; 2017; 84(3):110-117. PubMed ID: 28724844
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome and toxic epidermal necrolysis treatments: An Internet survey.
Curtis JA; Christensen LC; Paine AR; Collins Brummer G; Summers EM; Cochran AL; Petersen MJ; Hull CM
J Am Acad Dermatol; 2016 Feb; 74(2):379-80. PubMed ID: 26775781
[No Abstract] [Full Text] [Related]
13. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies.
Barron SJ; Del Vecchio MT; Aronoff SC
Int J Dermatol; 2015 Jan; 54(1):108-15. PubMed ID: 24697283
[TBL] [Abstract][Full Text] [Related]
14. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.
Torres-Navarro I; Briz-Redón Á; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):159-171. PubMed ID: 32946187
[TBL] [Abstract][Full Text] [Related]
17. Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in Toxic Epidermal Necrolysis, Steven-Johnsons Syndrome, and TEN/SJS Overlap - Metanalysis and metaregression of observational studies.
Krajewski A; Maciejewska-Markiewicz D; Jakubczyk K; Markowska M; Strużyna J; Mądry R; Mazurek M; Skonieczna-Żydecka K
Burns; 2022 Mar; 48(2):263-280. PubMed ID: 34903405
[TBL] [Abstract][Full Text] [Related]
18. Interventions for toxic epidermal necrolysis.
Majumdar S; Mockenhaupt M; Roujeau J; Townshend A
Cochrane Database Syst Rev; 2002; 2002(4):CD001435. PubMed ID: 12519556
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine in SJS/TEN management: a brief review.
Shokeen D
Cutis; 2016 Mar; 97(3):E17-8. PubMed ID: 27023091
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
